Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

The current study was designed to examine the effects of infused ANP on respiratory (FEV1), cardiovascular (blood pressure and pulse), and metabolic (plasma cGMP) function in asthmatic patients.

Why It Was Studied

Atrial natriuretic peptide (ANP) has bronchodilator and vasodilator properties thought to be mediated through the generation of cyclic guanylyl monophosphate (cGMP).

Measurements were repeated at the end of each 20-min period.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

As a double-blind ANP (Atrial Natriuretic Peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the ANP (Atrial Natriuretic Peptide) group a baseline to be compared against.

In the crossover set-up each of the participants took both ANP (Atrial Natriuretic Peptide) and the comparison in turn, acting as their own control.

What Was Measured

Measurements were repeated at the end of each 20-min period.

Topics PubMed links to this paper include Albuterol, Asthma, Atrial Natriuretic Factor, Blood Pressure, Bronchi, Cyclic GMP and Forced Expiratory Volume.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide).

The publication is from 1993 (The American review of respiratory disease), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.